摘要
目的:探究两种不同新辅助化疗方案对乳腺癌患者近期疗效及生存率的影响。方法:选取2016年3月-2017年3月笔者所在医院诊治的乳腺癌患者74例,按新辅助化疗方案的不同分为TE组(37例)和TEC组(37例)。TE组患者采用多西他赛+表柔比星(TE方案)进行化疗,TEC组患者在TE组基础上加用环磷酰胺(TEC方案)进行治疗。比较两组患者近期疗效及2年生存率。结果:TE组治疗总有效率为78.38%,TEC治疗总有效率为81.08%,两组比较差异无统计学意义(P>0.05)。TEC组2年生存率为91.89%,高于TE组的72.97%,差异有统计学意义(P<0.05)。结论:TE方案与TEC方案治疗乳腺癌的临床疗效相当,但TEC方案治疗乳腺癌的2年生存率更高。
Objective:To investigate the effect of two different neoadjuvant chemotherapy regimens on the short-term efficacy and survival rate of breast cancer patients.Method:A total of 74 patients with breast cancer diagnosed and treated in our hospital from March 2016 to March 2017 were selected.They were divided into the TE group(n=37)and the TEC group(n=37)according to different neoadjuvant chemotherapy regimens.The TE group received Docetaxel and Epirubicin(TE regimen)for chemotherapy,while the TEC group received Cyclophosphamide(TEC regimen)for treatment on the basis of TE group.The short-term efficacy and 2-year survival rate were compared between the two groups.Result:The total effective rate of TE group was 78.38%,and 81.08%of TEC group.There was no significant difference between the two groups(P>0.05).The 2-year survival rate in TEC group was 91.89%,which was higher than 72.97%in TE group,the difference was statistically significant(P<0.05).Conclusion:The clinical efficacy of TE regimen is similar to that of TEC regimen for breast cancer,but the 2-year survival rate of TEC regimen for breast cancer is higher.
作者
段海瑞
DUAN Hairui(Daye People’s Hospital,Daye 435100,China)
出处
《中外医学研究》
2019年第35期131-132,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
新辅助化疗
乳腺癌
生存
TE
TEC
Neoadjuvant chemotherapy
Breast cancer
Survival
TE
TEC
